Etrolizumab outperforms placebo in achieving clinical remission for Crohn's disease - Page 2

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-10-19T20:15:27+05:30 | Updated On 19 Oct 2022 8:15 PM IST

Maintenance phase TEA	etrolizumab, n=217	Placebo, n=217
Injection site erythema	6	14
Arthralgia	5	8
Headache	5	7

The most common serious adverse event was an exacerbation of Crohn's disease seen in 14 [6%] of 217 patients taking a placebo and four [2%] of 217 patients taking 105 mg etrolizumab in the maintenance cohort.

Thus, the trial revealed that etrolizumab was successful in attaining clinical remission and endoscopic improvement in a significantly higher proportion of patients with moderately to severely active Crohn's disease during the maintenance phase but the same could not be achieved during the induction phase.

Further reading: https://doi.org/10.1016/S2468-1253(22)00303-X

Sandborn WJ, Panés J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomized, placebo-controlled, double-blind, phase 3 trial [published online ahead of print, 2022 Oct 11]. Lancet Gastroenterol Hepatol. 2022; S2468-1253(22)00303-X.

Etrolizumabanti-β7 monoclonal antibodyα4β7 integrinsαEβ7 integrinsCrohn

Source : The LANCET Gastroenterology and Hepatology

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751